233 related articles for article (PubMed ID: 9122991)
1. Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.
Lodge JP; Pollard SG
Transplant Proc; 1997; 29(1-2):272-3. PubMed ID: 9122991
[No Abstract] [Full Text] [Related]
2. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
Buchholz B; Korn A
Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
[No Abstract] [Full Text] [Related]
3. Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group.
Korn A; Färber L; Maibücher A; Buchholz B; Offermann G
Transplant Proc; 1997 Nov; 29(7):2945-7. PubMed ID: 9365623
[No Abstract] [Full Text] [Related]
4. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
5. Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment.
Abendroth D; Buchholz B; Land W; May G; Wiesel M; Färber L; Korn A; Maibücher A
Transplant Proc; 1997; 29(1-2):275-6. PubMed ID: 9122993
[No Abstract] [Full Text] [Related]
6. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
[TBL] [Abstract][Full Text] [Related]
7. Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation.
Maccherini M; Bernazzali S; Diciolla F; Giunti G; Bizzarri F; Lisi GF; Davoli G; Biagioli B; Giomarelli PP; Simeone F; Caciorgna M; Marchetti L; Pula G; Sani G; Toscano M
Transplant Proc; 1998 Aug; 30(5):1904-5. PubMed ID: 9723327
[No Abstract] [Full Text] [Related]
8. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group.
Niese D
Transplant Proc; 1995 Apr; 27(2):1849-56. PubMed ID: 7725531
[No Abstract] [Full Text] [Related]
9. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
10. A one-year comparative study of Neoral vs Consupren in de novo renal transplant patients.
Stephan A; Masri MA; Barbari A; Aoun S; Rizk S; Kamel G
Transplant Proc; 1998 Nov; 30(7):3533-4. PubMed ID: 9838547
[No Abstract] [Full Text] [Related]
11. A randomized, controlled trial to assess the safety of switching stable renal transplant patients from Sandimmun to Sandimmun Neoral.
Loo CS; Morad Z; Lim TO; Fan KS; Suleiman AB
Transplant Proc; 1996 Jun; 28(3):1328-9. PubMed ID: 8658680
[No Abstract] [Full Text] [Related]
12. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA
Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
Taesch S; Niese D
Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of Neoral in transplant recipients.
Feutren G; Wong R; Jin J; Niese D; Mellein B
Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193
[No Abstract] [Full Text] [Related]
15. Therapeutic approach with patient-specific cyclosporine administration protocol in renal transplantation.
Sernyak PS; Chernobrivtsev PA; Kalinin DI; Lunyova AG; Denisov VK
Transplant Proc; 1997; 29(1-2):296. PubMed ID: 9123003
[No Abstract] [Full Text] [Related]
16. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.
Machado PG; Felipe CR; Hanzawa NM; Park SI; Garcia R; Alfieri F; Franco M; Silva HT; Medina-Pestana JO
Clin Transplant; 2004 Feb; 18(1):28-38. PubMed ID: 15108768
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
Shah MB; Martin JE; Schroeder TJ; First MR
Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
[No Abstract] [Full Text] [Related]
18. Neoral induction in pediatric renal transplantation.
Bunchman TE; Parekh RS; Flynn JT; Smoyer WE; Kershaw DB; Valentini RP; Pontillo BJ; Sandvordenker J; Brown C; Sedman AB
Pediatr Nephrol; 1998 Jan; 12(1):2-5. PubMed ID: 9502556
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
Offermann G; Korn A
Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
[No Abstract] [Full Text] [Related]
20. Neoral versus Sandimmune in kidney transplantation.
Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
